4SC 202

Drug Profile

4SC 202

Alternative Names: 4SC-202

Latest Information Update: 19 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nycomed
  • Developer 4SC
  • Class Antineoplastics; Benzamides; Pyrazoles; Pyrroles; Small molecules; Sulfones
  • Mechanism of Action BRD4 protein modulators; HDAC1 protein inhibitors; HDAC2 protein inhibitors; HDAC3 protein inhibitors; Lysine specific demethylase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Malignant melanoma
  • Preclinical Pancreatic cancer; Small cell lung cancer
  • No development reported Cancer; Haematological malignancies

Most Recent Events

  • 17 Apr 2018 Pharmacodynamics data from a preclinical study in Cancer presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)
  • 21 Mar 2018 4SC plans the phase II EMERGE study for Gastrointestinal tumours in combination with the anti-PD-L1 checkpoint inhibitor avelumab in the first half of 2018
  • 21 Mar 2018 4 SC plans a pivotal trial in Merckle cell carcinoma based on the data from SENSITIZE and EMERGE trials
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top